E. A. Naryshkina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
E. A. Naryshkina has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Anna G. Komarova
Botkin Hospital
3 shared publications - Denis Anatolevich Andreev
Sechenov First Moscow State Medical University (Sechenov University)
2 shared publications - Dmitrij Alekseevitch Sychev
Petrovsky National Research Centre of Surgery; Russian Medical Academy of Continuous Professional Education
2 shared publications - Kirill E. Eroshkin
Moscow Multidisciplinary Scientific and Clinical Center n.a. S.P. Botkin
2 shared publications - Maria I. Chashkina
Sechenov First Moscow State Medical University
2 shared publications - Aleksey A. Kulesh
Acad. E.A. Vagner Perm State Medical University, Ministry of Health of Russia; City Clinical Hospital Four
1 shared publication
Latest Publications
- Open Access
- 14 January 2026
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 21 (5) , 415-422
Plasma concentrations of factor Xa inhibitors and stroke risk in patients with atrial fibrillation
Aim . To determine plasma concentrations of direct oral anticoagulants (DOACs) in patients with ischemic stroke (IS) associated with atrial fibrillation (AF) and to compare them with DOAC levels in patients with AF but without IS receiving similar therapy. Material and methods. A prospective cohort study was conducted at the Vascular Center of S.P. Botkin Moscow City Clinical Hospital from April 2022 to April 2023. The study included 82 patients with cardioembolic stroke on the background of AF (main group) and 130 AF patients without stroke or transient ischemic attack (TIA) (control group). All patients had been receiving DOACs (apixaban or rivaroxaban) for at least 3 months. Diagnostic workup included brain computed tomography, сarotid ultrasound, laboratory tests, and stroke severity assessment by NIH Stroke Scale (NIHSS). Plasma DOAC concentrations were measured by high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). The lower limit of quantification (LLOQ) was 5 ng/mL. Results . Patients in the main group had significantly more frequent subtherapeutic DOAC concentrations below the LLOQ compared to the control group (52.4% vs. 1.5%, pConclusion . A significant proportion of patients with AF and cardioembolic ischemic stroke exhibit plasma concentrations of DOACs below LLOQ, which may contribute to stroke occurrence despite prescribed therapy. These findings emphasize the need to develop clinical criteria for selecting patients who require DOAC concentration monitoring and personalized therapy to reduce the risk of thrombotic events.
- 14 January 2026
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 21 (5) , 415-422
Open AccessPlasma concentrations of factor Xa inhibitors and stroke risk in patients with atrial fibrillation
Aim . To determine plasma concentrations of direct oral anticoagulants (DOACs) in patients with ischemic stroke (IS) associated with atrial fibrillation (AF) and to compare them with DOAC levels in patients with AF but without IS receiving similar therapy. Material and methods. A prospective cohort study was conducted at the Vascular Center of S.P. Botkin Moscow City Clinical Hospital from April 2022 to April 2023. The study included 82 patients with cardioembolic stroke on the background of AF (main group) and 130 AF patients without stroke or transient ischemic attack (TIA) (control group). All patients had been receiving DOACs (apixaban or rivaroxaban) for at least 3 months. Diagnostic workup included brain computed tomography, сarotid ultrasound, laboratory tests, and stroke severity assessment by NIH Stroke Scale (NIHSS). Plasma DOAC concentrations were measured by high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). The lower limit of quantification (LLOQ) was 5 ng/mL. Results . Patients in the main group had significantly more frequent subtherapeutic DOAC concentrations below the LLOQ compared to the control group (52.4% vs. 1.5%, pConclusion . A significant proportion of patients with AF and cardioembolic ischemic stroke exhibit plasma concentrations of DOACs below LLOQ, which may contribute to stroke occurrence despite prescribed therapy. These findings emphasize the need to develop clinical criteria for selecting patients who require DOAC concentration monitoring and personalized therapy to reduce the risk of thrombotic events.
- Open Access
- 30 June 2025
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 21 (2) , 149-154
Anticoagulant therapy in patients with cardioembolic subtype of ischemic stroke and atrial fibrillation
Aim. To evaluate the characteristics of anticoagulant therapy (ACT) use in patients with cardioembolic (CE) subtype ischemic stroke (IS) and atrial fibrillation (AF) hospitalized in a specialized vascular center.Material and methods. A cross-sectional study was conducted at the Vascular Center of Botkin City Clinical Hospital from April 2022 to April 2023. Adults (≥18 years) with confirmed CE-subtype IS and documented AF, presenting within 12 hours of symptom onset and receiving anticoagulants for over one month prior to admission, were eligible. Patients with hemorrhagic stroke or non-CE IS subtypes, those lacking data on anticoagulant use, or those who declined to participate were excluded.Results. Among 1.038 patients with IS, 215 (20.7%) were diagnosed with the CE subtype in the setting of AF. More than half (n=109) were not receiving ACT at the time of stroke onset. A total of 106 patients who had been on outpatient ACT were included; rivaroxaban (n=56), apixaban (n=30), dabigatran etexilate (n=11), and warfarin (n=9). The mean patient age was 77.8 years, with an average CHA2DS2-VASc score of 6. In 33.9% of patients, the prescribed doses of direct oral anticoagulant (DOAC) did not correspond to clinical guidelines (e.g., unjustified dose reductions of rivaroxaban and apixaban were identified). The median National Institutes of Health Stroke Scale (NIHSS) score at admission was 7, and in-hospital mortality reached 30.2%. Elevated mortality was associated with severe stroke presentation (NIHSS score > 8 in half of the patients) and a high burden of comorbidities: hypertension in 95.2%, chronic heart failure in 60.4%, type 2 diabetes mellitus in 30.1%, and prior myocardial infarction in 37.7% of patients.Conclusion. The high incidence of IS despite ongoing anticoagulation highlights the need for routine monitoring of DOAC plasma levels, regular assessment of treatment adherence, and systematic education of patients and their families regarding the importance of strict adherence to prescribed anticoagulant regimens.
- 30 June 2025
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 21 (2) , 149-154
Open AccessAnticoagulant therapy in patients with cardioembolic subtype of ischemic stroke and atrial fibrillation
Aim. To evaluate the characteristics of anticoagulant therapy (ACT) use in patients with cardioembolic (CE) subtype ischemic stroke (IS) and atrial fibrillation (AF) hospitalized in a specialized vascular center.Material and methods. A cross-sectional study was conducted at the Vascular Center of Botkin City Clinical Hospital from April 2022 to April 2023. Adults (≥18 years) with confirmed CE-subtype IS and documented AF, presenting within 12 hours of symptom onset and receiving anticoagulants for over one month prior to admission, were eligible. Patients with hemorrhagic stroke or non-CE IS subtypes, those lacking data on anticoagulant use, or those who declined to participate were excluded.Results. Among 1.038 patients with IS, 215 (20.7%) were diagnosed with the CE subtype in the setting of AF. More than half (n=109) were not receiving ACT at the time of stroke onset. A total of 106 patients who had been on outpatient ACT were included; rivaroxaban (n=56), apixaban (n=30), dabigatran etexilate (n=11), and warfarin (n=9). The mean patient age was 77.8 years, with an average CHA2DS2-VASc score of 6. In 33.9% of patients, the prescribed doses of direct oral anticoagulant (DOAC) did not correspond to clinical guidelines (e.g., unjustified dose reductions of rivaroxaban and apixaban were identified). The median National Institutes of Health Stroke Scale (NIHSS) score at admission was 7, and in-hospital mortality reached 30.2%. Elevated mortality was associated with severe stroke presentation (NIHSS score > 8 in half of the patients) and a high burden of comorbidities: hypertension in 95.2%, chronic heart failure in 60.4%, type 2 diabetes mellitus in 30.1%, and prior myocardial infarction in 37.7% of patients.Conclusion. The high incidence of IS despite ongoing anticoagulation highlights the need for routine monitoring of DOAC plasma levels, regular assessment of treatment adherence, and systematic education of patients and their families regarding the importance of strict adherence to prescribed anticoagulant regimens.
- 8 November 2023
- Published by Alfmed LLC in Medical alphabet
- No. 25,p. 14-20
Anticoagulant therapy in patients with atrial fibrillation and chronic kidney disease: Arguments for or against
Atrial fibrillation and chronic renal failure are common diseases in the population with similar risk factors. Both conditions are independent riskfactors for the development of thromboembolic complications. There is compelling evidence to support the benefits of anticoagulant therapy for atrial fibrillation in the general population, but in patients with advanced chronic renal failure, the use of anticoagulants may be limited. A number of studies have shown conflicting results, and this topic is of interest for further discussion and a comprehensive analysis of the existing data.
- 8 November 2023
- Published by Alfmed LLC in Medical alphabet
- No. 25,p. 14-20
Anticoagulant therapy in patients with atrial fibrillation and chronic kidney disease: Arguments for or against
Atrial fibrillation and chronic renal failure are common diseases in the population with similar risk factors. Both conditions are independent riskfactors for the development of thromboembolic complications. There is compelling evidence to support the benefits of anticoagulant therapy for atrial fibrillation in the general population, but in patients with advanced chronic renal failure, the use of anticoagulants may be limited. A number of studies have shown conflicting results, and this topic is of interest for further discussion and a comprehensive analysis of the existing data.